A game changer in HIV prevention in sub-Saharan African women. Cabotegravir, a long-acting injectable antiretroviral drug, provides eight weeks of protection against acquisition of HIV. A clinical trial comparing cabotegravir to the current preexposure prophylaxis, a daily pill combining emtricitabine and tenofovir disoproxil fumarate (TDF), was stopped early because cabotegravir was clearly superior. Although both drugs prevented HIV, cabotegravir was 89% more effective than emtricitabine-TDF. In a briefing, Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, noted that the availability of a long-acting injectable drug overcomes many of the barriers faced by those who need it most, women in sub-Saharan Africa. According to UNAIDS, women and girls in sub-Saharan Africa account for 59% of all new HIV infections.